Genmab A/S (NASDAQ:GMAB) Releases Earnings Results, Beats Expectations By $0.20 EPS

Genmab A/S (NASDAQ:GMAB) announced its quarterly earnings results on Thursday. The company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.36 by $0.20, Zacks reports. The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.20 billion. Genmab A/S had a net margin of 16.97% and a return on equity of 13.96%.

Here are the key takeaways from Genmab A/S’s conference call:

• Genmab reported 22% revenue growth for the first nine months of 2026 and 9% growth in adjusted operating profit. Management said growth is becoming more diversified, with roughly half of revenue growth coming from outside DARZALEX.
• Commercial momentum continued: EPKINLY sales rose 47% to $491 million, while TIVDAK sales increased 9% to $131 million. Genmab highlighted broader EPKINLY adoption and continued TIVDAK growth in Japan and Europe.
• The company announced three positive Phase III readouts in October: EPKINLY in frontline DLBCL, Rina-S in platinum-resistant ovarian cancer, and petosemtamab in first-line head and neck cancer. Genmab sees potential launches beginning in 2027, though the medicines remain subject to regulatory review.
• Genmab maintained its 2026 guidance, expects revenue in the upper part of its $4.325–$4.525 billion range, and said adjusted operating profit should finish above the midpoint of its guidance range.
• Management cautioned that fourth-quarter operating expenses will rise significantly due to manufacturing, clinical development, and launch-readiness work for Rina-S and petosemtamab.

Genmab A/S Price Performance

Shares of GMAB traded up $0.89 during mid-day trading on Friday, reaching $53.63. 7,827,783 shares of the stock traded hands, compared to its average volume of 6,032,240. The company has a market cap of $33.47 billion, a price-to-earnings ratio of 45.84, a price-to-earnings-growth ratio of 2.11 and a beta of 0.73. Genmab A/S has a 1 year low of $23.62 and a 1 year high of $59.97. The firm has a fifty day moving average price of $39.18 and a 200 day moving average price of $31.11. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81.

Analysts Set New Price Targets

A number of brokerages have issued reports on GMAB. Morgan Stanley boosted their target price on shares of Genmab A/S from $42.00 to $57.00 and gave the company an “equal weight” rating in a report on Friday, October 30th. HC Wainwright raised their price target on Genmab A/S from $50.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. Guggenheim lifted their price target on Genmab A/S from $58.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Truist Financial reiterated a “buy” rating and set a $67.00 price objective (up from $45.00) on shares of Genmab A/S in a research note on Thursday, October 29th. Finally, Weiss Ratings upgraded Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, September 1st. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Genmab A/S presently has an average rating of “Moderate Buy” and a consensus price target of $53.61.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases.

The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.

Genmab operates internationally, with activities across Europe, North America and Asia.